Protein from lean sources also promotes GLP-1 release while helping maintain muscle massan important consideration for anyone working on their healthy weight goals
The FDA declared the tirzepatide shortage resolved in October 2024, which closed the main legal pathway for large-scale compounding
During your consultation, Dr
Still, insurance coverage and cost considerations mean both drugs remain relevant, and patient-centred conversations about therapy choice are critical. GLP-1s beyond weight loss as multi-system therapies Liver disease and metabolic steatohepatitis Non-alcoholic fatty liver disease (NAFLD) and the more severe metabolic dysfunction-associated steatohepatitis (MASH) have few effective pharmacologic treatments
Kodera R, Shikata K, Kataoka HU, et al
These patches are marketed as a convenient, needle-free alternative to GLP-1 injections, which sounds appealing if youre anxious about needles